Back to Search Start Over

Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken?

Authors :
Francesco Natale
Riccardo Molinari
Rosa Franzese
Noemi Mollo
Giovanni Cimmino
Natale, Francesco
Molinari, Riccardo
Franzese, Rosa
Mollo, Noemi
Cimmino, Giovanni
Source :
Future Pharmacology. 3:392-406
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

The goal in cardiovascular prevention is the reduction of morbidity and mortality through the promotion of healthy lifestyles in the general population. The management of modifiable risk factors with pharmacological and non-pharmacological interventions, based on the individual risk is the first strategy suggested by the current guidelines. Several epidemiological studies have clearly shown the direct correlation between high levels of low-density lipoprotein cholesterol (LDL-C) and incidence of cardiovascular diseases. On the other hand, numerous randomized clinical studies have reported a huge benefit in terms of major cardiovascular events achievable by the reduction of LDL-C, thus supporting the notion that “the lower is better”. Among the lipid-lowering strategies, statins are the drugs of choice in cardiovascular prevention, at both primary and secondary level. To achieve the ambitious targets suggested by the current guidelines, other lipid-lowering therapies are currently available in addition to statins, such as ezetimibe the inhibitors of the PCSK9. Pharmacological research has recently led to the development of a new drug, the bempedoic acid, which further enrich the available therapies. This drug also acts on the biosynthesis of cholesterol but at upstream level than statins. From the biochemical point of view, it has the potential to be considered before the statin with consequent titration of statins to achieve the desirable LDL-C target. In the present review, the biochemical and pharmacological characteristics of bempedoic acid are discussed. An overview of the clinical data that support its use in the management of the cardiovascular patient and its allocation in the lipid-lowering scenario will be also provided.

Details

ISSN :
26739879
Volume :
3
Database :
OpenAIRE
Journal :
Future Pharmacology
Accession number :
edsair.doi.dedup.....8dcf54dc1559f6d528f3ec42df0532bf